Skip to content
AnalystLens

Charles River Laboratories International Quarterly Report for Q1 Ended Mar 29, 2025

Filing Date
Filed May 7, 2025
Period End
March 29, 2025
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed May 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported first-quarter 2025 results (three months ended March 29, 2025) with total revenue of $984.2 milliona, down $27.4 million, or 2.7%, from $1,011.6 million a year earlier.

The decline was driven mainly by lower volume in the DSA segment, where clients continued to spend cautiously, with smaller declines in RMS and Manufacturing. Operating income fell to $74.7 millionb (7.6% of revenue) from $126.0 million (12.5%), reflecting lower revenue, $65.3 million of intangible amortization (including $35.5 million of accelerated amortization tied to lost key CDMO customers), restructuring charges of $23.8 million, and third-party legal costs in DSA. Net income attributable to the company's common shareholders declined to $25.5 million, or $0.50 per diluted share, from $67.3 million, or $1.30 per diluted share.

Cash generation improved, with operating cash flow of $171.7 millionc versus $129.9 million, helped by lower variable compensation payments and favorable supplier payment timing. The company spent $350.0 million repurchasing 2.1 million shares under its $1.0 billion authorization, leaving $549.3 million available, and net revolving credit facility borrowings of $267.5 million raised total debt and finance leases to $2.53 billion. Cash and cash equivalents were $229.4 million at quarter-end, and the company reports that it believes existing funds and financing access are sufficient for the foreseeable future.

The filing also flags ongoing risks: U.S. DOJ, USFWS, and SEC investigations into non-human primate sourcing, securities and derivative lawsuits, new tariffs affecting supply from Vietnam, Mauritius, and China, and reduced NIH funding and FDA moves to reduce animal testing. On May 6, 2025, the company entered a Cooperation Agreement with a large shareholder and agreed to a comprehensive strategic review overseen by the Strategic Partnership and Capital Allocation Committee.

Key Highlights

  1. Total revenue of $984.2 million, down 2.7% year over year, with the decline driven primarily by lower DSA volume amid cautious client spending.
  2. Operating income of $74.7 million (7.6% of revenue) versus $126.0 million (12.5%) a year earlier, pressured by $65.3 million of intangible amortization and $23.8 million of restructuring charges.
  3. Manufacturing segment posted an operating loss of $8.6 million, compared with operating income of $33.7 million, due to $35.5 million of accelerated CDMO client relationship amortization.
  4. Diluted EPS of $0.50 versus $1.30 a year earlier; net income attributable to common shareholders of $25.5 million versus $67.3 million.
  5. Operating cash flow rose to $171.7 million from $129.9 million, while $350.0 million was spent repurchasing 2.1 million shares, leaving $549.3 million under the $1.0 billion authorization.
  6. Total debt and finance leases increased to $2.53 billion from $2.26 billion, driven by $267.5 million of net revolving credit facility borrowings.
  7. On May 6, 2025, the company agreed to a strategic review of alternatives under a Cooperation Agreement with a large shareholder, creating uncertainty for investors.

Financial Statements

Q1 FY2025 against Q1 FY2024

Line itemQ1 FY2025Q1 FY2024Change
Revenue$984.17M$1.01B−2.7%
SG&A Expenses$177.80M$186.29M−4.6%
Operating Income$74.67M$125.98M−40.7%
Net Income$25.47M$67.33M−62.2%
EPS (Basic)$0.50$1.31−61.8%
EPS (Diluted)$0.50$1.30−61.5%
Shares Outstanding (Basic)50.68M51.44M−1.5%
Shares Outstanding (Diluted)50.85M51.84M−1.9%

Frequently Asked Questions

  1. Why did operating income decline so sharply in the quarter?

    Operating income fell to $74.7 million from $126.0 million, mainly because of lower revenue in the DSA segment, higher intangible amortization of $65.3 million versus $32.6 million (including $35.5 million of accelerated amortization on CDMO client relationships after the loss of key customers), restructuring charges of $23.8 million, and third-party legal costs related to government investigations.

  2. How is the company funding share repurchases and debt levels?

    The company repurchased 2.1 million shares for $350.0 million and paid $19.1 million for the remaining 8% interest in Vital River, funded in part by $416.3 million of new borrowings and $267.5 million of net Credit Facility proceeds. Total debt and finance leases rose to $2.53 billion, and the weighted average interest rate on debt was 4.59%.

  3. What are the main legal and regulatory risks disclosed?

    The company continues to cooperate with DOJ, USFWS, and SEC investigations into non-human primate shipments from Cambodia, and has voluntarily suspended such shipments to the U.S. A securities class action is on appeal to the First Circuit, with oral arguments on May 5, 2025, and two derivative lawsuits are stayed. The company says it cannot estimate potential exposure or loss for these matters.

  4. What does the company say about tariffs and government funding?

    The filing says new tariffs remain in effect on trade with countries that supply significant inputs, including Vietnam, Mauritius, and China, and the company plans to offset most estimated tariffs by passing costs to clients. It also notes that a February 2025 NIH policy limiting indirect overhead payments is subject to a preliminary injunction, and that clients at academic institutions could delay purchases if government funding is reduced.